Growth hormone deficiency medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(19 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Growth hormone deficiency}}
{{Growth hormone deficiency}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{MAD}}  


==Overview==
==Overview==
Growth hormone (GH) supplementation is indicated for children with GH deficiency whose epiphyses are yet to close. The dose for children is between 0.16 and 0.24 mg/kg/week, divided into once daily injections. Serum levels of insulin-like growth factor I (IGF-I) ought to be measured continuously for several weeks after starting GH treatment or making a dose adjustment. Side effects of GH supplementation include headaches, idiopathic intracranial hypertension, slipped capital femoral epiphysis, worsening of existing scoliosis, pancreatitis, and gynecomastia. There is a likely role for GH in cancer risk.
==Medical Therapy==
==Medical Therapy==


=== Children treatment ===
=== Childhood GH deficiency treatment ===
 
Indications:
==== '''Indications''' 10-13 ====
* Treatment with [[Growth hormone|Growth hormone (GH)]] is indicated for children with [[Growth hormone|GH]] deficiency whose [[Epiphysis|epiphyses]] are yet to close.  
* Treatment with GH is indicated for children with GH deficiency whose epiphyses are open.  
* Treatment should be continued after linear growth ceases until full skeletal development.
* Treatment should be continued until linear growth ceases or even beyond.
Dosing:
 
==== Dosing ====
* The dose for children is between 0.16 and 0.24 mg/kg/week, divided into once daily injections.
* The dose for children is between 0.16 and 0.24 mg/kg/week, divided into once daily injections.
* The dose for patients with severe GH deficiency is 20 micrograms/kg/day.
* The dose for patients with severe [[Growth hormone|GH]] deficiency is 20 micrograms/kg/day.
 
Dosing during puberty:
==== '''Dosing during puberty''' ====
* A temporary increase in [[Growth hormone|GH]] dose is preferred if the patient failed to respond to normal doses.  
* A temporary increase in GH dose (eg, to 70 to 100 micrograms/kg/day) has been suggested in case of failed proper response to treatment. [21]
* Although, effective treatment with GH before [[puberty]] is more efficacious than efforts to treat patients during [[puberty]].
* Although, effective treatment with GH prior to puberty is more efficacious and cost-effective than efforts to boost growth during puberty.
Monitoring:
 
* Serum levels of [[Insulin-like growth factor 1|insulin-like growth factor I]] (IGF-I) should be measured for several weeks after beginning [[Growth hormone|GH]] treatment or making a dose adjustment.
==== '''Monitoring''' ====
* This helps to avoid very high [[Insulin-like growth factor-I|IGF-I]] levels, which are thought to be associated with some of the drug's toxicity as recommended in guidelines from the Pediatric Endocrine Society (PES):<ref name="pmid27884013">{{cite journal| author=Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB et al.| title=Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. | journal=Horm Res Paediatr | year= 2016 | volume= 86 | issue= 6 | pages= 361-397 | pmid=27884013 | doi=10.1159/000452150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27884013  }}</ref>
* Serum levels of insulin-like growth factor I (IGF-I) should be measured several weeks after beginning GH treatment or making a dose adjustment.
* This helps to avoid very high IGF-I levels, which are thought to be associated with some of the drug's toxicity.
* as recommended in guidelines from the Pediatric Endocrine Society (PES) [14]:
 
* If the IGF-I level is below this target range, increase the dose of GH because GH is unlikely to be efficacious if IGF-I levels are very low.
* If the IGF-I level is above this target range (ie, >+2 SD), we reduce the GH dose to prevent GH toxicity.
* For patients with multiple pituitary hormone deficiencies, adrenal and thyroid function should be reassessed a few months after initiation of GH therapy and periodically by measuring 8 to 9 AM serum cortisol and free T4, respectively [14]
 
==== '''Duration of therapy''' ====
Treatment is continued at least until linear growth decreases to less than 2.0 to 2.5 cm (0.8 to 1 inch)/year [14].
 
More than two-thirds of patients have normal results when retested for GH deficiency as adults.
 
It is important to repeat the GH stimulation test during the transition period to determine if they will require ongoing therapy.
 
GH deficiency is usually permanent in patients with genetic causes of GH deficiency (recognized by a family history of GH deficiency), structural causes of GH deficiency (eg, optic nerve hypoplasia), or organic GH deficiency (eg, caused by brain surgery, brain tumors, intracranial irradiation, or associated with multiple pituitary hormone deficiencies).
 
==== '''Growth response to GH therapy''' ====
if GH is administered at an early age, patients can achieve adult height within the midparental target height range [17,18].
 
recheck length or height at least every four to six months and calculate the height velocity to determine whether the growth response is adequate (algorithm 1)
 
During the initial "catch-up" growth period, the 75<sup>th</sup> percentile curve for height velocity is an appropriate target to define an adequate growth response to GH.
 
Catch-up growth should continue until the child's height percentile is in the expected range Children who have an inadequate growth response to GH therapy should be reevaluated. The causes can be categorized by the IGF-I level
 
'''IGF-I level below target range''' 
 
Poor adherence to GH treatment or a technical issue in its administration.
 
Sub-therapeutic dose of GH.
 
The patient has GH deficiency, but has concurrent mild GH insensitivity.
 
Development of neutralizing antibodies to GH – Patients who develop neutralizing antibodies to GH tend to have an initial typical growth response to GH treatment over the first three to six months, and then suddenly have a diminution of their growth rate, with low levels of IGF-I despite adequate dosing of GH, reflecting acquired GH insensitivity. This problem may occur in patients with GH deficiency due to a ''GH1'' gene deletion (also referred to as isolated GH deficiency type IA,
 
The diagnosis is supported by serum testing for antihuman GH antibodies, and/or by genetic testing to determine whether the patient's GH deficiency is caused by a GH gene deletion. These patients respond favorably to treatment with recombinant human IGF-I (mecasermin).  
 
'''IGF-I level variable'''
 
IGF-I levels vary depending on the patient's nutritional status, but usually are below the normal range or in the low end of the normal range
 
Development of central hypothyroidism
 
Patients with multiple pituitary hormone deficiencies are at risk for treatment-emergent hypothyroidism because GH enhances conversion of thyroxine (T4) to triiodothyronine (T3).
 
The patient has comorbid disease that limits growth (eg, inflammatory bowel disease or untreated celiac disease).
 
==== '''OUTCOMES OF GROWTH HORMONE THERAPY''' ====
 
===== '''Growth''' =====
better response to GH therapy were younger age at start of GH treatment
 
greater bone age delay at initiation of therapy, and more severe GH deficiency [23]
 
===== '''Bone mass''' =====
Children with GH deficiency have low bone mass compared with age- and size-matched control children.
 
To maximize peak bone mass, it is important to consider the continuation of GH treatment even after linear growth has ceased until full skeletal   [24].
 
These findings suggest that GH therapy increases bone mass and the progression toward peak bone mass [26]. Without adequate GH replacement, either childhood- or adult-onset GH deficiency can be associated with low bone mass during adulthood  27,28
 
==== '''ADVERSE EFFECTS OF GROWTH HORMONE THERAPY''' ====
Treatment of children with recombinant human GH has generally been safe [29-31].
 
===== '''Acute effects''' =====
* Headaches which usually are benign.
* Idiopathic intracranial hypertension (formerly known as pseudotumor cerebri), increased intraocular pressure [32] usually resolves with discontinuation of GH therapy. Treatment can often be resumed at a lower dose without return of symptoms back up to standard doses.
* Slipped capital femoral epiphysis [33] routine monitoring is recommended for suggestive symptoms such as hip and/or knee pain, and changes in gait. This condition usually requires surgical pinning of the capital femoral epiphysis.  
* Worsening of existing scoliosis [29]
* Pancreatitis
* Gynecomastia
* increase in the growth and pigmentation of nevi, without malignant degeneration [29,34]
* Carpal tunnel syndrome, edema, and arthralgia are more common in adults undergoing GH treatment but are unusual in children.
* Most usually occur soon after therapy is initiated, and some of these effects are probably caused by sodium and water retention [35]. Rarely, a child treated with GH develops neutralizing antibodies, resulting in loss of efficacy [36,37].
* Development of insulin resistance and disorders of glucose intolerance may occur in children receiving GH therapy (especially those with predisposing conditions, eg, Prader Willi syndrome), but the overall clinical significance appears to be low. An international surveillance program of 23,333 children and adolescents receiving GH identified 18 new cases of type 2 diabetes mellitus and 14 of impaired glucose tolerance [38]. Although these numbers were higher than expected as compared with historical controls, the number of patients affected is small. The incidence of type 1 diabetes mellitus is not increased by GH therapy.
 
===== Cronic effects =====
Concerns have been raised about a possible role for GH or its mediator insulin-like growth factor-I (IGF-I) in cancer risk; these concerns are primarily based on observations that higher IGF-I levels in normal individuals are associated with increased risks for breast or prostate cancer [39].
 
Several observational studies have attempted to determine whether GH treatment affects cancer risk. Although there is some disagreement among studies, the preponderance of data leads to the following conclusions:


For patients with '''isolated growth failure''' (isolated GH deficiency, idiopathic short stature, or prenatal growth failure) and no other risk factors, GH therapy does not increase the risk for leukemia or other cancers compared with the age-matched general population. The best information comes from the Safety and Appropriateness of GH treatments in Europe (SAGhE) study, which followed almost 24,000 patients, approximately one-half of whom had isolated growth failure [40]. In long-term follow-up, the patients with isolated growth failure had no overall increase in cancer risk (Standardized Incidence Ratio [SIR] 1.0; 95% CI 0.6-1.4) or cancer mortality. The certainty about this conclusion is somewhat limited because of the rarity of cancer in this cohort (23 cases among 11,062 treated subjects) and limited length of follow-up (mean 14.8 years per patient). However, a lack of association with cancer was also found in prior studies with shorter length of follow-up [41-45], including some that focused primarily on leukemia [46-48].
* If the [[Insulin-like growth factor-I|IGF-I]] level is below the target range, increasing the dose of [[Growth hormone|GH]] is recommended, as [[Growth hormone|GH]] is unlikely to be efficacious if [[Insulin-like growth factor-I|IGF-I]] levels are very low.
* If the IGF-I level is above this target range, we reduce the GH dose to prevent GH toxicity. For patients with more than one pituitary hormone deficiencies, adrenal and thyroid function need to be reassessed a few months after initiation of GH therapy.<ref name="pmid27884013" />
Duration of therapy :
* Treatment is continued at least until linear growth decreases to less than 2.0 to 2.5 cm.
* More than two-thirds of patients have normal outcomes when retested for GH deficiency as adults.
* It is vital to repeat the GH stimulation test at some point of the transition period to determine if they will require ongoing therapy.
* Patients can attain normal height if treatment is administered at an early age.
* Patient's height should be reevaluated every 4 to 6 months to determine if the growth response is adequate.
* During the preliminary growth period, the 75th percentile curve for height pace is the proper target as an adequate growth response to GH..


For patients with a '''primary cancer diagnosis''' that led to the GH treatment, recombinant GH was associated with a modest increase in risk for a secondary cancer (SIR 7.6, 95% CI 6.1-9.6) [40]. The increased risk was significant for a variety of secondary cancers including bone, melanoma, kidney, brain, thyroid, and leukemia. Cancer mortality increased with GH dose and duration of treatment. Since childhood cancer patients are known to be at increased risk for secondary cancers, due to the underlying cancer itself and/or cancer-directed therapy (especially radiation), the increased incidence of secondary cancers among these patients may or may not be related to the GH treatment.
=== Effect of treatment ===
Growth :
* [[Growth hormone|GH]] therapy started early in childhood have better prognosis.<ref name="pmid12114235">{{cite journal| author=Carel JC, Ecosse E, Nicolino M, Tauber M, Leger J, Cabrol S et al.| title=Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. | journal=BMJ | year= 2002 | volume= 325 | issue= 7355 | pages= 70 | pmid=12114235 | doi= | pmc=117125 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12114235  }}</ref>
* Increase in height continues for more than 2 years even after cessation of treatment.<ref>{{Cite journal


Prior smaller studies of childhood cancer survivors who had been treated with GH noted little or no increased risk for secondary malignancy, except for the development of benign meningiomas after radiation treatment of certain primary brain tumors [49-52].
| author = [[Z. Laron]], [[B. Klinger]], [[S. Anin]], [[A. Pertzelan]] & [[P. Lilos]]
| title = Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature
| journal = [[Journal of pediatric endocrinology & metabolism : JPEM]]
| volume = 10
| issue = 2
| pages = 191–196
| year = 1997
| month = March-April
| pmid = 9364352
}}</ref>
Bone mass :
* Children with [[Growth hormone|GH]] deficiency have low [[bone mass]] compared with normal children.
* To maximize [[bone mass]], it is important to consider the continuation of treatment even after linear growth has ceased until full skeletal development.<ref name="pmid19324976">{{cite journal| author=Conway GS, Szarras-Czapnik M, Racz K, Keller A, Chanson P, Tauber M et al.| title=Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. | journal=Eur J Endocrinol | year= 2009 | volume= 160 | issue= 6 | pages= 899-907 | pmid=19324976 | doi=10.1530/EJE-08-0436 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19324976  }}</ref>
* [[Growth hormone|GH]] therapy increases bone mass.<ref name="pmid1874933">{{cite journal| author=Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R| title=Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. | journal=J Clin Endocrinol Metab | year= 1991 | volume= 73 | issue= 3 | pages= 555-63 | pmid=1874933 | doi=10.1210/jcem-73-3-555 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1874933  }}</ref>
* Without adequate GH replacement, [[Growth hormone|GH]] deficiency can be associated with low [[bone mass]] during adulthood.<ref name="pmid8126140">{{cite journal| author=Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM| title=Reduced bone mineral density in patients with adult onset growth hormone deficiency. | journal=J Clin Endocrinol Metab | year= 1994 | volume= 78 | issue= 3 | pages= 669-74 | pmid=8126140 | doi=10.1210/jcem.78.3.8126140 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8126140  }}</ref>


For patients with '''other non-cancer primary diagnoses''' that led to GH treatment (eg, Turner syndrome or hypopituitarism without cancer), there was a modest increase in cancer risk (SIR 1.4, 95% CI 1.1-1.9), primarily due to an excess of bone or bladder cancer, although based on small numbers for each site [40].
=== Adverse effects of growth hormone therapy===
Treatment of children with [[Recombinant DNA|recombinant]] human [[Growth hormone|GH]] has generally been safe.<ref name="pmid9745413">{{cite journal| author=Saenger P, Attie KM, DiMartino-Nardi J, Hintz R, Frahm L, Frane JW| title=Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. | journal=J Clin Endocrinol Metab | year= 1998 | volume= 83 | issue= 9 | pages= 3115-20 | pmid=9745413 | doi=10.1210/jcem.83.9.5089 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9745413  }}</ref><ref name="pmid20523016">{{cite journal| author=Carel JC, Butler G| title=Safety of recombinant human growth hormone. | journal=Endocr Dev | year= 2010 | volume= 18 | issue=  | pages= 40-54 | pmid=20523016 | doi=10.1159/000316126 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20523016  }}</ref>


For children with cancer (including craniopharyngioma) who develop GH deficiency, guidelines suggest a 12-month waiting period after completion of cancer-directed therapy to confirm that the cancer was eradicated before initiating GH therapy [14].
Acute effects :
* [[Headache|Headaches]] which usually are benign.
* [[Idiopathic intracranial hypertension]] (known as [[Idiopathic intracranial hypertension|pseudotumor cerebri]]), increased [[Intraocular pressure (IOP)|intraocular pressure]] usually resolves with discontinuation of [[Growth hormone|GH]] therapy. Treatment can often be resumed at a lower dose without the return of symptoms back up to standard doses.<ref name="pmid22727870">{{cite journal| author=Youngster I, Rachmiel R, Pinhas-Hamiel O, Bistritzer T, Zuckerman-Levin N, de Vries L et al.| title=Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure. | journal=J Pediatr | year= 2012 | volume= 161 | issue= 6 | pages= 1116-9 | pmid=22727870 | doi=10.1016/j.jpeds.2012.05.024 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22727870  }}</ref>
* [[Slipped capital femoral epiphysis]]: routine monitoring is recommended for suggestive symptoms such as hip and/or [[knee pain]], and changes in [[gait]]. This condition requires surgical pinning of the [[Epiphysis|capital femoral epiphysis]].<ref name="pmid18174706">{{cite journal| author=Darendeliler F, Karagiannis G, Wilton P| title=Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. | journal=Horm Res | year= 2007 | volume= 68 Suppl 5 | issue=  | pages= 41-7 | pmid=18174706 | doi=10.1159/000110474 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18174706  }}</ref>
* Worsening of existing [[scoliosis]].<ref name="pmid8626820">{{cite journal| author=Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R| title=Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 5 | pages= 1704-10 | pmid=8626820 | doi=10.1210/jcem.81.5.8626820 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8626820  }}</ref>
* [[Pancreatitis]]
* [[Gynecomastia]]
* Increase in the growth and [[pigmentation]] of [[Nevus|nevi]].<ref name="pmid8099381">{{cite journal| author=Bourguignon JP, Piérard GE, Ernould C, Heinrichs C, Craen M, Rochiccioli P et al.| title=Effects of human growth hormone therapy on melanocytic naevi. | journal=Lancet | year= 1993 | volume= 341 | issue= 8859 | pages= 1505-6 | pmid=8099381 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8099381  }}</ref>
* [[Carpal tunnel syndrome]], [[edema]], and [[arthralgia]] are more common in adults than in children.
* [[Antibodies|Neutralizing antibodies]] against [[Growth hormone|GH]] may be formed resulting in loss of [[efficacy]].<ref name="pmid12014526">{{cite journal| author=Pitukcheewanont P, Schwarzbach L, Kaufman FR| title=Resumption of growth after methionyl-free human growth hormone therapy in a patient with neutralizing antibodies to methionyl human growth hormone. | journal=J Pediatr Endocrinol Metab | year= 2002 | volume= 15 | issue= 5 | pages= 653-7 | pmid=12014526 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12014526  }}</ref>
* Development of [[insulin resistance]] and [[glucose intolerance]] may occur in children receiving [[Growth hormone|GH]] therapy.<ref name="pmid10696981">{{cite journal| author=Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB et al.| title=Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. | journal=Lancet | year= 2000 | volume= 355 | issue= 9204 | pages= 610-3 | pmid=10696981 | doi=10.1016/S0140-6736(99)04055-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10696981  }}</ref>
Chronic effects:
* There is a possible role for [[Growth hormone|GH]] in cancer risk especially [[prostate cancer]].<ref name="pmid12147365">{{cite journal| author=Giovannucci E, Pollak M| title=Risk of cancer after growth-hormone treatment. | journal=Lancet | year= 2002 | volume= 360 | issue= 9329 | pages= 268-9 | pmid=12147365 | doi=10.1016/S0140-6736(02)09561-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12147365  }}</ref><ref name="pmid26227295">{{cite journal| author=Swerdlow AJ, Cooke R, Albertsson-Wikland K, Borgström B, Butler G, Cianfarani S et al.| title=Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone. | journal=Horm Res Paediatr | year= 2015 | volume= 84 | issue= 3 | pages= 172-83 | pmid=26227295 | doi=10.1159/000435856 | pmc=4611066 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26227295  }}</ref>
* [[Growth hormone|GH]] therapy does not increase the risk of [[leukemia]] or other cancers compared with the general population.<ref name="pmid281872252">{{cite journal| author=Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel JC et al.| title=Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. | journal=J Clin Endocrinol Metab | year= 2017 | volume= 102 | issue= 5 | pages= 1661-1672 | pmid=28187225 | doi=10.1210/jc.2016-2046 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28187225  }}</ref>
* For patients with a primary cancer diagnosis that led to the [[Growth hormone|GH]] treatment, [[recombinant]] [[GH]] was associated with an increase in risk for [[cancer]].<ref name="pmid281872252" />
* The increased risk was significant for a variety of secondary cancers including [[Bone|bone,]] [[melanoma]], [[kidney]], [[brain]], [[thyroid]] cancer and [[leukemia]].
* For children with [[cancer]], guidelines suggest a 12-month period after completion of cancer-directed therapy to confirm that the [[cancer]] was eradicated before initiating [[Growth hormone|GH therapy]].


'''Treatment protocol''' 
=== Transition of GH treatment from childhood to adults ===
* GH is administered by subcutaneous injection once a day, usually in the evening.
* The transition period between childhood treatment and adults treatment begins in late [[puberty]] and ends with full adult maturation.
* The initial goal is to start with a lower than maintenance dose and to gradually increase the dose (to minimize side effects).  
* Children treated with [[Growth hormone|GH]] should be retested if they have persistence of GHD near the time of reaching adulthood.
* The starting dose should be 2 to 5 mcg/kg body weight once daily toward the lower end of the range for men, women taking estrogen transdermally, and those over age 60 years, and the upper end for women taking estrogen orally. This weight-based recommendation is for the starting dose only. The goal should be to start with low doses and increase gradually until the serum IGF-1 concentration is normal.
* Patients with idiopathic GHD usually do not need [[Growth hormone|GH]] treatment anymore, children with organic causes of GHD usually are found to have GHD on retesting.  
* The eventual goal is to find the GH dose that maintains the serum IGF-1 concentration within the middle of the age-adjusted normal range [4]. [26]
* Retesting involves measurement of [[Insulin-like growth factor-I|IGF-I]] and stimulation with [[insulin]]-induced [[hypoglycemia]] or [[arginine]].
* Most studies have shown benefit of [[Growth hormone|GH]] treatment in young adults with GHD in [[body composition]], especially the achievement of peak [[bone mass]].  


* If the serum IGF-1 concentration has not increased to within the normal range after two months, the daily dose should be increased stepwise in 1 to 2 mcg/kg increments at two-month intervals until it is normal. A dose of greater than 10 to 12 mcg/kg is not likely to be needed.
=== Adult-type GH deficiency treatment ===
* If side effects occur or the serum IGF-1 concentration increases to above normal at any dose, the dose should be decreased.
Treatment protocol:
'''Duration of therapy'''
* [[Growth hormone|GH]] is administered by subcutaneous injection once a day, usually in the evening.
* recommend continuing treatment indefinitely.
* The goal should be to start with low doses and increase gradually until the serum [[Insulin-like growth factor-I|IGF-1]] concentration is normal.
* A systematic review of 23 studies of long-term GH therapy suggests that it may have some sustained benefits for body composition, lipid profile, carotid intima media thickness, and BMD but not for muscle strength [62]. [63]
* The eventual goal is to find the [[Growth hormone|GH]] dose that maintains the serum [[Insulin-like growth factor-I|IGF-1]] concentration within the middle of the age-adjusted normal range.<ref name="pmid27736313">{{cite journal| author=Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R et al.| title=Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 11 | pages= 3888-3921 | pmid=27736313 | doi=10.1210/jc.2016-2118 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27736313  }}</ref>
* Stopping the treatment causes an increase in C-reactive protein and increases in both LDL and HDL cholesterol but improved insulin sensitivity and decreased glycated hemoglobin (A1C).
* If side effects occur or the serum [[Insulin-like growth factor-I|IGF-1]] concentration increases to above normal at any dose, the dose should be decreased.
'''Monitoring''' 
Dosing:
* Measurement of serum IGF-1 is probably the best single test of the adequacy of GH treatment [64].
* The starting dose should be 2 to 5 mcg/kg body weight once daily.
* GH treatment should increase the serum IGF-1 concentration to within, but not higher than, the age-specific range of normal to avoid over replacement.
Duration of therapy:
* We suggest measuring a serum IGF-1 two months after starting therapy.
* Treatment should be continued indefinitely.<ref name="pmid23572082">{{cite journal| author=Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR| title=Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. | journal=Eur J Endocrinol | year= 2013 | volume= 169 | issue= 1 | pages= R1-14 | pmid=23572082 | doi=10.1530/EJE-12-1088 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23572082  }}</ref>
* if the serum concentration is below the normal age-specific range, the daily GH dose should be increased stepwise in 1 to 2 mcg increments at two-month intervals until it is within the normal range.
* Stopping the treatment causes an increase in [[C-reactive protein (CRP)|C-reactive protein]] and increases in both [[LDL Cholesterol|LDL]] and [[HDL Cholesterol|HDL]] cholesterol but improved [[insulin]] [[sensitivity]] and decreased glycated [[hemoglobin]] [[Hemoglobin A1c|(A1C]]).<ref name="pmid22791760">{{cite journal| author=Filipsson Nyström H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, Johannsson G| title=Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency. | journal=J Clin Endocrinol Metab | year= 2012 | volume= 97 | issue= 9 | pages= 3185-95 | pmid=22791760 | doi=10.1210/jc.2012-2006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22791760  }}</ref>
* Once serum IGF-1 is in the normal range, we suggest repeating it every 6 to 12 months.  
Monitoring:
* If IGF-1 is ever above normal, the GH dose should be decreased by 1 to 2 mcg/kg increments and serum IGF-1 should be repeated every two months until it returns to the normal range.
* Measurement of serum [[Insulin-like growth factor-I|IGF-1]] is probably the best single test of the adequacy of [[Growth hormone|GH]] treatment.<ref name="pmid8636336">{{cite journal| author=de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E| title=Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 4 | pages= 1371-7 | pmid=8636336 | doi=10.1210/jcem.81.4.8636336 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8636336  }}</ref>
* Measurment of  serum [[Insulin-like growth factor-I|IGF-1]] two months after starting therapy is recommended.
* GH treatment should increase the serum [[Insulin-like growth factor-I|IGF-1]] concentration to within, but not higher than, the age-specific range of normal to avoid over replacement.
* Once serum [[Insulin-like growth factor-I|IGF-1]] is in the normal range, repeat measurements every 6 to 12 months is recommended.  
* If [[Insulin-like growth factor-I|IGF-1]] is ever above normal, the [[Growth hormone|GH]] dose should be decreased by 1 to 2 mcg/kg increments and serum [[Insulin-like growth factor-I|IGF-1]] should be repeated every 2 months until it returns to the normal range.


==References==
==References==

Latest revision as of 19:41, 27 October 2017

Growth hormone deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Growth hormone deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Growth hormone deficiency medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Growth hormone deficiency medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Growth hormone deficiency medical therapy

CDC on Growth hormone deficiency medical therapy

Growth hormone deficiency medical therapy in the news

Blogs on Growth hormone deficiency medical therapy

Directions to Hospitals Treating Growth hormone deficiency

Risk calculators and risk factors for Growth hormone deficiency medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Growth hormone (GH) supplementation is indicated for children with GH deficiency whose epiphyses are yet to close. The dose for children is between 0.16 and 0.24 mg/kg/week, divided into once daily injections. Serum levels of insulin-like growth factor I (IGF-I) ought to be measured continuously for several weeks after starting GH treatment or making a dose adjustment. Side effects of GH supplementation include headaches, idiopathic intracranial hypertension, slipped capital femoral epiphysis, worsening of existing scoliosis, pancreatitis, and gynecomastia. There is a likely role for GH in cancer risk.

Medical Therapy

Childhood GH deficiency treatment

Indications:

  • Treatment with Growth hormone (GH) is indicated for children with GH deficiency whose epiphyses are yet to close.
  • Treatment should be continued after linear growth ceases until full skeletal development.

Dosing:

  • The dose for children is between 0.16 and 0.24 mg/kg/week, divided into once daily injections.
  • The dose for patients with severe GH deficiency is 20 micrograms/kg/day.

Dosing during puberty:

  • A temporary increase in GH dose is preferred if the patient failed to respond to normal doses.
  • Although, effective treatment with GH before puberty is more efficacious than efforts to treat patients during puberty.

Monitoring:

  • Serum levels of insulin-like growth factor I (IGF-I) should be measured for several weeks after beginning GH treatment or making a dose adjustment.
  • This helps to avoid very high IGF-I levels, which are thought to be associated with some of the drug's toxicity as recommended in guidelines from the Pediatric Endocrine Society (PES):[1]
  • If the IGF-I level is below the target range, increasing the dose of GH is recommended, as GH is unlikely to be efficacious if IGF-I levels are very low.
  • If the IGF-I level is above this target range, we reduce the GH dose to prevent GH toxicity. For patients with more than one pituitary hormone deficiencies, adrenal and thyroid function need to be reassessed a few months after initiation of GH therapy.[1]

Duration of therapy :

  • Treatment is continued at least until linear growth decreases to less than 2.0 to 2.5 cm.
  • More than two-thirds of patients have normal outcomes when retested for GH deficiency as adults.
  • It is vital to repeat the GH stimulation test at some point of the transition period to determine if they will require ongoing therapy.
  • Patients can attain normal height if treatment is administered at an early age.
  • Patient's height should be reevaluated every 4 to 6 months to determine if the growth response is adequate.
  • During the preliminary growth period, the 75th percentile curve for height pace is the proper target as an adequate growth response to GH..

Effect of treatment

Growth :

  • GH therapy started early in childhood have better prognosis.[2]
  • Increase in height continues for more than 2 years even after cessation of treatment.[3]

Bone mass :

  • Children with GH deficiency have low bone mass compared with normal children.
  • To maximize bone mass, it is important to consider the continuation of treatment even after linear growth has ceased until full skeletal development.[4]
  • GH therapy increases bone mass.[5]
  • Without adequate GH replacement, GH deficiency can be associated with low bone mass during adulthood.[6]

Adverse effects of growth hormone therapy

Treatment of children with recombinant human GH has generally been safe.[7][8]

Acute effects :

Chronic effects:

  • There is a possible role for GH in cancer risk especially prostate cancer.[15][16]
  • GH therapy does not increase the risk of leukemia or other cancers compared with the general population.[17]
  • For patients with a primary cancer diagnosis that led to the GH treatment, recombinant GH was associated with an increase in risk for cancer.[17]
  • The increased risk was significant for a variety of secondary cancers including bone, melanoma, kidney, brain, thyroid cancer and leukemia.
  • For children with cancer, guidelines suggest a 12-month period after completion of cancer-directed therapy to confirm that the cancer was eradicated before initiating GH therapy.

Transition of GH treatment from childhood to adults

  • The transition period between childhood treatment and adults treatment begins in late puberty and ends with full adult maturation.
  • Children treated with GH should be retested if they have persistence of GHD near the time of reaching adulthood.
  • Patients with idiopathic GHD usually do not need GH treatment anymore, children with organic causes of GHD usually are found to have GHD on retesting.
  • Retesting involves measurement of IGF-I and stimulation with insulin-induced hypoglycemia or arginine.
  • Most studies have shown benefit of GH treatment in young adults with GHD in body composition, especially the achievement of peak bone mass.

Adult-type GH deficiency treatment

Treatment protocol:

  • GH is administered by subcutaneous injection once a day, usually in the evening.
  • The goal should be to start with low doses and increase gradually until the serum IGF-1 concentration is normal.
  • The eventual goal is to find the GH dose that maintains the serum IGF-1 concentration within the middle of the age-adjusted normal range.[18]
  • If side effects occur or the serum IGF-1 concentration increases to above normal at any dose, the dose should be decreased.

Dosing:

  • The starting dose should be 2 to 5 mcg/kg body weight once daily.

Duration of therapy:

Monitoring:

  • Measurement of serum IGF-1 is probably the best single test of the adequacy of GH treatment.[21]
  • Measurment of serum IGF-1 two months after starting therapy is recommended.
  • GH treatment should increase the serum IGF-1 concentration to within, but not higher than, the age-specific range of normal to avoid over replacement.
  • Once serum IGF-1 is in the normal range, repeat measurements every 6 to 12 months is recommended.
  • If IGF-1 is ever above normal, the GH dose should be decreased by 1 to 2 mcg/kg increments and serum IGF-1 should be repeated every 2 months until it returns to the normal range.

References

  1. ↑ 1.0 1.1 Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB; et al. (2016). "Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency". Horm Res Paediatr. 86 (6): 361–397. doi:10.1159/000452150. PMID 27884013.
  2. ↑ Carel JC, Ecosse E, Nicolino M, Tauber M, Leger J, Cabrol S; et al. (2002). "Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry". BMJ. 325 (7355): 70. PMC 117125. PMID 12114235.
  3. ↑ Z. Laron, B. Klinger, S. Anin, A. Pertzelan & P. Lilos (1997). "Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature". Journal of pediatric endocrinology & metabolism : JPEM. 10 (2): 191–196. PMID 9364352. Unknown parameter |month= ignored (help)
  4. ↑ Conway GS, Szarras-Czapnik M, Racz K, Keller A, Chanson P, Tauber M; et al. (2009). "Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency". Eur J Endocrinol. 160 (6): 899–907. doi:10.1530/EJE-08-0436. PMID 19324976.
  5. ↑ Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R (1991). "Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence". J Clin Endocrinol Metab. 73 (3): 555–63. doi:10.1210/jcem-73-3-555. PMID 1874933.
  6. ↑ Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM (1994). "Reduced bone mineral density in patients with adult onset growth hormone deficiency". J Clin Endocrinol Metab. 78 (3): 669–74. doi:10.1210/jcem.78.3.8126140. PMID 8126140.
  7. ↑ Saenger P, Attie KM, DiMartino-Nardi J, Hintz R, Frahm L, Frane JW (1998). "Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group". J Clin Endocrinol Metab. 83 (9): 3115–20. doi:10.1210/jcem.83.9.5089. PMID 9745413.
  8. ↑ Carel JC, Butler G (2010). "Safety of recombinant human growth hormone". Endocr Dev. 18: 40–54. doi:10.1159/000316126. PMID 20523016.
  9. ↑ Youngster I, Rachmiel R, Pinhas-Hamiel O, Bistritzer T, Zuckerman-Levin N, de Vries L; et al. (2012). "Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure". J Pediatr. 161 (6): 1116–9. doi:10.1016/j.jpeds.2012.05.024. PMID 22727870.
  10. ↑ Darendeliler F, Karagiannis G, Wilton P (2007). "Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database". Horm Res. 68 Suppl 5: 41–7. doi:10.1159/000110474. PMID 18174706.
  11. ↑ Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R (1996). "Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience". J Clin Endocrinol Metab. 81 (5): 1704–10. doi:10.1210/jcem.81.5.8626820. PMID 8626820.
  12. ↑ Bourguignon JP, Piérard GE, Ernould C, Heinrichs C, Craen M, Rochiccioli P; et al. (1993). "Effects of human growth hormone therapy on melanocytic naevi". Lancet. 341 (8859): 1505–6. PMID 8099381.
  13. ↑ Pitukcheewanont P, Schwarzbach L, Kaufman FR (2002). "Resumption of growth after methionyl-free human growth hormone therapy in a patient with neutralizing antibodies to methionyl human growth hormone". J Pediatr Endocrinol Metab. 15 (5): 653–7. PMID 12014526.
  14. ↑ Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB; et al. (2000). "Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment". Lancet. 355 (9204): 610–3. doi:10.1016/S0140-6736(99)04055-6. PMID 10696981.
  15. ↑ Giovannucci E, Pollak M (2002). "Risk of cancer after growth-hormone treatment". Lancet. 360 (9329): 268–9. doi:10.1016/S0140-6736(02)09561-2. PMID 12147365.
  16. ↑ Swerdlow AJ, Cooke R, Albertsson-Wikland K, Borgström B, Butler G, Cianfarani S; et al. (2015). "Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone". Horm Res Paediatr. 84 (3): 172–83. doi:10.1159/000435856. PMC 4611066. PMID 26227295.
  17. ↑ 17.0 17.1 Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel JC; et al. (2017). "Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study". J Clin Endocrinol Metab. 102 (5): 1661–1672. doi:10.1210/jc.2016-2046. PMID 28187225.
  18. ↑ Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R; et al. (2016). "Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 101 (11): 3888–3921. doi:10.1210/jc.2016-2118. PMID 27736313.
  19. ↑ Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR (2013). "Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review". Eur J Endocrinol. 169 (1): R1–14. doi:10.1530/EJE-12-1088. PMID 23572082.
  20. ↑ Filipsson Nyström H, Barbosa EJ, Nilsson AG, Norrman LL, Ragnarsson O, Johannsson G (2012). "Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency". J Clin Endocrinol Metab. 97 (9): 3185–95. doi:10.1210/jc.2012-2006. PMID 22791760.
  21. ↑ de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E (1996). "Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers". J Clin Endocrinol Metab. 81 (4): 1371–7. doi:10.1210/jcem.81.4.8636336. PMID 8636336.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Growth_hormone_deficiency_medical_therapy&oldid=1381007"